Trial Profile
A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients With MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6 Years of Age
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Idursulfase (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shire; Takeda
- 30 Apr 2019 Planned number of patients changed from 20 to 21.
- 30 Apr 2019 Planned End Date changed from 1 Aug 2022 to 9 Jul 2025.
- 30 Apr 2019 Planned primary completion date changed from 1 Feb 2022 to 9 Jul 2025.